Neuraxis

Yahoo Finance • 7 days ago

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in... Full story

Yahoo Finance • last month

NeurAxis, Inc. Announces Preferred Stock Dividend

CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in child... Full story

Yahoo Finance • 7 months ago

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures... Full story

Yahoo Finance • 9 months ago

NeurAxis reports Q2 results

* NeurAxis press release [https://seekingalpha.com/pr/20197157-neuraxis-reports-strong-second-quarter-2025-financial-results-driven-by-a-46-percent-growth] (NYSE:NRXS [https://seekingalpha.com/symbol/NRXS]): Q2 Net loss in the second qua... Full story

Yahoo Finance • 10 months ago

Neuraxis ends Masimo license agreement and launches employee stock plan

Neuraxis, Inc. (NYSE American:NRXS), a $23 million market cap healthcare company with annual revenue of $2.93 million and impressive year-over-year growth of 27.5%, disclosed on Thursday that it has terminated its license and collaboration... Full story